Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Chemoradiotherapy in High-Risk HNSCC
NCT04814069Phase 2Unknown
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Disease-Free Survival at 1 year. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04814069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814069.